Tuesday, 20 Mar 2018

You are here

Increasing Incidence of Paradoxical Autoimmune Disease with Biologics?

With the increasing use of biologic therapies to treat rheumatic disease has come an awareness of a small but real risk of developing de novo autoimmune disease.

In the poster hall this morning, Soledad Retamozo (Argentina) presented an abstract (#210) where through a literature-based searched they analyzed number of reported cases of autoimmune disease triggered by biologics. Through a systemic and yearly MEDLINE search cases were collected in a registry (aeBIOGAS) and totaled 12,013 cases since 2006. This included over 50 different autoimmune disease and different types of biologics, not just from the rheum world (also checkpoint inhibitors, VEGF inhibitors, etc.). The most frequently reported were PsO (n=6,377), IBD (n=783) and demyelinating CNS disease (n=783). TNF inhibitors were associated with 9,220 cases (adalimumab 4,051, infliximab 3,109, etanercept 1496), and rituximab with 664. They also displayed in impressive figure depicting the exponential increase in number of paradoxical autoimmune diseases seen with biologics.

At first blush these numbers are mind-blowing and do suggest that autoimmunity attends a wide variety of biologics with various mechanisms of action. The question, however, is are the diseases occurring exponentially or is this reporting bias (increase in use/number of drugs) and/or channeling bias. For example, they reported 49% of the cases of ILD were seen with rituximab – we often treat patients with ILD with rituximab.

While this is an interesting study, cautionary notes are that we do not know if these diseases are truly being observed more or this is merely result of publication bias. To me, it underlines the importance paradoxical autoimmune disease with biologics but further conclusions will require more robust studies.


Add new comment

More Like This

MMWR: Arthritis Prevalence Increases and Varies Widely

MMWR reports that In 2015, the number of adults with arthritis continued to increase; with marked geographic variability in arthritis estimates with gaps in arthritis management.

The CDC estimates that physician-diagnosed arthritis affects 54 million of adults in the United States with an annual cost of approximately $300 billion annually.

The RheumNow Week in Review - 16 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

The RheumNow Week in Review - 9 March 2018

Dr. Jack Cush reviews highlights, news and recent research published this past week on RheumNow.com. This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.

ACR Responds to Association Health Plans Proposed Rule

In comments submitted today to the US Department of Labor in response to its Association Health Plans (AHP) proposed rule, the American College of Rheumatology urged Administration officials to protect essential health benefits and other consumer protections that make it possible for individuals living with rheumatic diseases to access comprehensive and affordable healthcare.

The RheumNow Week in Review - 2 March 2018

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com.